



(11) **EP 2 861 608 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
19.06.2019 Bulletin 2019/25

(45) Date of publication and mention
of the grant of the patent:
24.04.2019 Bulletin 2019/17

(21) Application number: **13806968.7**

(22) Date of filing: **19.06.2013**

(51) Int Cl.:
C07F 9/6561 ^(2006.01) **A61K 31/675** ^(2006.01)
A61P 31/04 ^(2006.01) **C07F 9/60** ^(2006.01)

(86) International application number:
PCT/IB2013/001780

(87) International publication number:
WO 2013/190384 (27.12.2013 Gazette 2013/52)

(54) **PRODRUG DERIVATIVES OF
(E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL)METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMIDE**

PRODRUG-DERIVATE VON (E)-N-METHYL-N-((3-METHYLBENZOFURAN-2-YL) METHYL)-3-(7-OXO-5,6,7,8-TETRAHYDRO-1,8-NAPHTHYRIDIN-3-YL)ACRYLAMID

DÉRIVÉS DE TYPE PROMÉDICAMENT DU (E)-N-MÉTHYL-N-((3-MÉTHYLBENZOFURAN-2-YL) MÉTHYL)-3-(7-OXO-5,6,7,8-TÉTRAHYDRO-L,8-NAPHTYRIDIN-3-YL)ACRYLAMIDE

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**
Designated Extension States:
BA ME

(30) Priority: **19.06.2012 US 201261661559 P**

(43) Date of publication of application:
22.04.2015 Bulletin 2015/17

(73) Proprietor: **Debiopharm International SA
1006 Lausanne (CH)**

(72) Inventors:
• **PARTRIDGE, John, J.**
Chapel Hill, NC 27516-6832 (US)
• **COLUCCI, John**
Kirkland, QC H9K 1S2 (CA)

- **GAREAU, Yves**
Notre-Dame de L'île-Perrot, QC J7V 7P2 (CA)
- **THERIEN, Michel**
Laval, QC H7R 4R2 (CA)
- **ZAMBONI, Robert**
Beaconsfield, QC H9W 5L4 (CA)
- **HAFKIN, Barry**
Austin, TX 78755 (US)
- **MARFAT, Anthony**
Mystic, CT 06355 (US)
- **ZAGHDANE, Helmi**
Pincourt, Québec J7W 0B9 (CA)

(74) Representative: **Hoffmann Eitle
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)**

(56) References cited:
**WO-A1-2008/098374 WO-A1-2010/151689
CA-A1- 2 776 849**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 861 608 B8